Navigation Links
Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
Date:5/12/2010

QUEBEC CITY, May 12 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. ( AEZS, TSX: AEZ) (the "Company"), a late-stage drug development company specialized in oncology and endocrine therapy, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational New Drug (IND) application for its doxorubicin targeted conjugate compound, AEZS-108, in luteinizing hormone releasing hormone (LHRH) receptor positive urothelial (bladder) cancer. Following this approval from the FDA, the Company expects to initiate a Phase 2 clinical trial in this indication in the second half of this year.

The study will be conducted at the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine with Gustavo Fernandez, M.D., Assistant Professor of Medicine, as the Principal Investigator, and will include up to 64 patients, male and female, with advanced LHRH-receptor positive urothelial (bladder) cancer. The study will be conducted in two parts; the first one will be a dose-finding part in up to 12 patients and then, the chosen dose will be studied for its effect on progression-free survival.

Juergen Engel, Ph.D., President and CEO of Aeterna Zentaris stated, "We are very pleased with the FDA's approval and excited about this Phase 2 trial in bladder cancer, since it will be our first with AEZS-108 in the United States, and the first one to include male patients. With this upcoming Phase 2 trial, as well as the current Phase 2 trial in advanced ovarian and endometrial cancer conducted in Europe, for which final results are expected before year-end, AEZS-108 has become a major component of our oncology portfolio."


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
2. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
3. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
4. AEterna Zentaris Announces Appointment of New Board Member
5. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
6. AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
7. AEterna Zentaris Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
8. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
9. AEterna Zentaris Receives US$5.5 Million from Institutional Investors
10. AEterna Zentaris to Raise US$5.5 Million from Institutional Investors at US$1.20 Per Share
11. AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin (AEZS-130) as First Oral Diagnostic Test for Growth Hormone Deficiency
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... Calif. , Nov. 24, 2014   Veracyte, Inc. ... Bonnie H. Anderson , president and chief executive officer, will ... 26 th Annual Healthcare Conference on Tuesday, December 2, ... . The live audio webcast and subsequent ... http://investor.veracyte.com . Please connect to the website at least 15 ...
(Date:11/24/2014)... 2014  Spherix Incorporated (Nasdaq: SPEX ... fostering and monetization of intellectual property, today provided ...  Case No. 3:13-cv-03494-M and  Spherix v. Uniden Corporation ... the United States District Court for the Northern ... On November 21, 2014 the Markman ...
(Date:11/22/2014)... (PRWEB) November 21, 2014 Prominent ... investors will gather on December 3rd at Genetic ... Conferences series. GeneticRx will take place at the ... School and will discuss the present and future ... exon skipping, and gene editing—as well as the ...
(Date:11/22/2014)... Rapids, MI (PRWEB) November 22, 2014 ... opportunity to simulate the proper management of life-like ... and test lung devices . Grand Rapids-based, Michigan ... plans to donate two of the respiratory simulation ... to $15,000 each. Grand Valley and Muskegon Community ...
Breaking Biology Technology:Veracyte to Present at the Piper Jaffray 26th Annual Healthcare Conference 2Markman Hearing Held as Scheduled in VTech and Uniden Cases 2Pioneering Academics and Key Industry Leaders to Discuss Rare Diseases and the Emergence of New Genetic Medicines at Genetic Rx on December 3rd 2Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 2Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 3
... Sept. 16 Metamark Genetics, Inc., a privately held ... optimize cancer care, announced today the appointment ... Dr. Blume-Jensen joins Metamark with over 20 ... discovery. From 2001 to 2008 Dr. Blume-Jensen was department ...
... Sept. 15 CryoLife, Inc. (NYSE: ... processing company, announced today that it will participate in the ... in New York City. D. Ashley Lee, executive ... CryoLife, Inc., will present a corporate overview on Tuesday, September ...
... 14, 2010 -- As industries and consumers increasingly seek ... Department of Energy,s Oak Ridge National Laboratory is providing ... A research team led by ORNL,s Nina Balke, ... type of scanning probe microscopy called electrochemical strain microscopy ...
Cached Biology Technology:Metamark Genetics, Inc. Announces New Chief Scientific Officer 2CryoLife to Present at UBS Global Life Sciences Conference 2ORNL scientists reveal battery behavior at the nanoscale 2
(Date:11/15/2014)... -- While we may still be a few years away from ... to gain instant access to all that ailed his patients, ... tablets for monitoring and measuring our health are cropping up ... a tad Orwellian to some, but a new survey suggests ... opportunities into their healthcare regime. These are some ...
(Date:11/10/2014)... detergent pods began appearing on U.S. store shelves in ... numbers ever since. The small packets can be tossed ... out a liquid or powder. The convenience, though, has ... study from researchers at Nationwide Children,s Hospital found that ... reports of 17,230 children younger than 6 years of ...
(Date:11/7/2014)... Florida , November 6, 2014 ... authentication for better mobile security revolutionizing online transactions.  Companies in ... Alibaba Holdings Ltd. (NYSE: BABA ), Google Inc. ... MSFT ), eBay Inc. (NASDAQ: EBAY ) and ... NXTD and NXTDW), a biometric authentication company focused ...
Breaking Biology News(10 mins):Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Study finds laundry detergent pods, serious poisoning risk for children 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6
... $50 billion in manufactured goods last year, according to ... $2.6 trillion. By 2011, over $15 billion in nano-enabled ... $3 billion in 2006. And industry experts project that ... consumer food products by 2010. Yet, ...
... Artificial teeth and crowns made of ceramic material are ... but that may change because of a technique that ... Oak Ridge National Laboratorys Materials Science and Technology Division has ... ceramics alters the surface structure. Nowadays, cracks begin at the ...
... Brussels & Leuven, Belgium As the most common ... carries enormous implications for our ageing society. It is ... peptide (A -peptide) protofibrils. Until now, the conditions under ... to the disease remained unknown. VIB researchers have now ...
Cached Biology News:FDLI, PEN co-sponsor major conference on nanotechnology 2FDLI, PEN co-sponsor major conference on nanotechnology 3Story tips from the Department of Energy's Oak Ridge National Laboratory, December 2007 2Story tips from the Department of Energy's Oak Ridge National Laboratory, December 2007 3Lipids in the brain an important factor for Alzheimer's disease? 2
RABBIT ANTI HALOPERIDOL...
Form: Ready to use Applications: Western Blot, ELISA...
... Analyzer for General Chemistries, Specialty Chemistries, QC, Reagent Development, Pharmaceutical Development, Physician Owned Labs, Drugs ... user-selectable wavelengths. ... ... ...
2,4,6, Trinitrophenyl hapten is conjugated to lipopolysaccharide (LPS)....
Biology Products: